HealthcareServices

Hepatitis D Industry Poised for Rapid Growth, Forecast to Touch $0.92 Billion by 2030 at 4.1% CAGR

February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the hepatitis d market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Hepatitis D Market reach by 2030 starting from 2026 levels?

The hepatitis d market size has shown consistent growth over recent years. It is projected to expand from $0.76 billion in 2025 to $0.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.4%. This historical expansion is attributable to several factors, including enhanced hepatitis B screening coverage, a greater understanding of HDV severity, improved diagnostic capabilities, an increase in referrals to specialty centers, and the introduction of targeted therapies.

The market for hepatitis d is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $0.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. Several factors will drive this growth during the forecast period, including intensified research into new HDV treatments, a heightened emphasis on combination antiviral therapies, the broadening of vaccination-related prevention approaches, increasing understanding among high-risk groups, and greater financial commitments to research into rare liver diseases. Key trends expected during this period involve a stronger focus on the early detection of co-infections, the expanded application of advanced serologic testing, an increasing need for specialized treatment plans, the wider implementation of hospital-based disease management, and improved emphasis on disease awareness.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp

Which Drivers Are Influencing Long-Term Growth In The Hepatitis D Market?

The rising occurrence of hepatitis B is anticipated to drive the expansion of the hepatitis D market in the future. Hepatitis B is defined as a viral ailment impacting the liver, manifesting symptoms like jaundice, tiredness, and discomfort in the abdomen, potentially progressing to chronic liver conditions or liver cancer without proper treatment. The surge in Hepatitis B instances stems from reasons including unsafe sexual encounters, the practice of sharing needles, vertical transmission from mother to child during birth, and inadequate vaccine distribution in specific areas. Hepatitis D depends on the Hepatitis B virus for its reproduction, utilizing Hepatitis B’s surface antigen to penetrate liver cells, thus establishing co-infection of these two viruses as a crucial element in the advancement of liver disease. For example, as reported in April 2025 by the Department of Health and Human Services, a US government agency, newly reported chronic hepatitis B cases reached 17,650 during 2023, with 1,769 hepatitis B-related fatalities also documented in 2023. Consequently, the growing incidence of hepatitis B is fueling the expansion of the hepatitis D market.

How Is The Hepatitis D Market Divided Into Segments?

The hepatitis d market covered in this report is segmented –

1) By Type: Acute, Chronic

2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies

4) By End-Users: Clinic, Hospital, Other End Users

Subsegments:

1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D

2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D

Which Trends Are Influencing The Development Of The Hepatitis D Market?

Leading firms within the hepatitis D sector are prioritizing the creation of novel treatments, including RNA-targeted antiviral therapy, with the goal of enhancing patient results and fulfilling unmet clinical requirements for chronic hepatitis D infection. This type of antiviral therapy functions by directly engaging a virus’s RNA to impede its ability to replicate, interfere with the creation of viral proteins, or deactivate viral genes, leading to a decrease in viral load and management of the infection. An example of this progress is seen in December 2024, when Vir Biotechnology Inc., a biotechnology firm based in the US, was granted both Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) status by the European Medicines Agency (EMA) for its combined treatment, tobevibart and elebsiran, aimed at chronic hepatitis delta (CHD).

Which Key Players Are Driving Competition In The Hepatitis D Market?

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report

Which Region Currently Holds The Largest Share Of The Hepatitis D Market?

North America was the largest region in the hepatitis D market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hepatitis D Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21202&type=smp

Browse Through More Reports Similar to the Global Hepatitis D Market 2026, By The Business Research Company

Hepatitis C Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-c-global-market-report

Viral Hepatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Vitamin D Market Report 2026

https://www.thebusinessresearchcompany.com/report/vitamin-d-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795